Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors

doi:10.3748/wjg.v21.i27.8271

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 27

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (12282)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-6) series.

Item

Count

PDF

747

WORD

224

HTML

5946

Tables (1-6)

421

Sum=7338

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

495

Download

1242

Sum=1737

Publishing Process of This Article

Item

Count

Browse

1307

Download

1900

Sum=3207

Jul 21, 2015 (publication date) through Apr 4, 2025

Times Cited of This Article

Times Cited (34)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Jul 21, 2015; 21(27): 8271-8283
Published online Jul 21, 2015. doi: 10.3748/wjg.v21.i27.8271

Table 1 Breast cancer studies n (%)

Author	Type of microsphere	Type of mets (patients)	Response criteria	Response	Median OS
(publish date and study type)	(average dosage or activity)	Type of mets (patients)	@ 1^st assessment	Response	Median OS
Gordon et al[50]	Therasphere	Breast (75)	RECIST and PET	RECIST	6.6 mo
(8/2014 Epub, RS)	(mean 1.52 Gbq)		@ 1.4 mo (median)	24 (35.3) PR
				43 (63.2) SD
				1 (1.5) PD
				7 lost
				PET
				3 (12) CR
				18 (72) PR or SD
				4 (16) PD
				50 lost
Seyal et al[48]	Unspecified	Breast (21)	RECIST 1.1	34 lesions	None
(8/2014, RS)	(no dosage info)	34 lesions	@ unspecified	6 (17.7) PR
				27 (79.4) SD
				1 (2.9) PD
Saxena et al[47]	SIR-Spheres	Breast (40)	RECIST	2 (5) CR	13.6 mo
(12/2013, RS)	(mean 1.67 Gbq)		@ 1 mo	10 (26) PR
				15 (39) SD
				11 (29) PD
				2 lost
Cianni et al[33]	SIR-Spheres	Breast (77)	RECIST and PET	29 (56) PR	11.5 mo
(1/2013, RS)	(median 1.9 Gbq)		@ 1.8 mo	18 (35) SD
				5 (10) PD
				25 ineligible
Jakobs et al[39]	SIR-Spheres	Breast (30)	RECIST	14 (61) PR	11.7 mo (all)
(5/2008, PC)	(mean 1.9 Gbq)		@ 4.2 mo (median)	8 (35) SD	23.6 mo (responders)
				1 (4) PD	5.7 mo (nonresponders)
				7 lost
Coldwell et al[35]	SIR-Spheres	Breast (44)	RECIST and PET	RECIST	Median OS not reached
(3/2007, RS)	(median 2.1 Gbq)		@ 2.8 mo	17 (47) PR
				17 (47) SD	86% 14-mo survival
				2 PD (5) PD
				8 lost
				PET scans
				42 (95) response
				2 (5) no response/progression
Bangash et al[31]	Therasphere	Breast (27)	WHO and PET	WHO	Median OS not given.
(5/2007, PC)	(median 1.70 Gbq, mean 2.05 Gbq)		@ 3 mo	9 (39.1) CR/PR	6.8 mo (ECOG 0)
				12 (52.1) SD	2.6 mo (ECOG 1,2,3)
				2 (8.8) PD 4 lost	9.4 mo (< 25% tumor burden)
				PET 17 (63) response	2.0 mo (> 25% tumor burden)
				10 (37) no response
Cianni et al[34]	SIR-Spheres	Breast (32, data extracted from larger study)	RECIST	14 (44) CR/PR	None
(1/2010, RS)	(mean 1.64 Gbq)		@ 1.8 mo	11 (34) SD
				7 (22) PD
Reiner et al[46]	SIR-Spheres	Breast (1, data extracted from larger study)	RECIST 1.1	1 (100) CR/PR	None
(1/2014, PC)	(mean 1.5 Gbq)	Breast (1, data extracted from larger study)	@ 4 mo	1 (100) CR/PR	None
Pöpperl et al[45]	SIR-Spheres	Breast (4, data extracted from larger study)	PET	3 (100) Regression	None
(4/2005, PC)	(mean 2.27 Gbq)	Breast (4, data extracted from larger study)	@ 3 mo	1 lost	None

PC: Prospective cohort study; RS: Retrospective study; CR: Complete response; PR: Progressive response; PD: Progressive disease; SD: Stable disease; OS: Overall survival; OR: Overall response.

Table 2 Cholangiocarcinoma studies n (%)

Author	Type of microsphere	Type of mets (patients)	Response criteria	Response	Median OS
(publish date and study type)	(average dosage or activity)	Type of mets (patients)	@ 1^st assessment	Response	Median OS
Ibrahim et al[69]	Therasphere	ICC (24)	WHO	6 (27) PR	14.9 mo
(10/2008, PC)	(median 105.1 Gy)		@ 1 mo	15 (68) SD
				1 (5) PD	31.8 mo (solitary)
				2 lost	6.1 mo (extrahepatic disease)
Saxena et al[71]	SIR-Spheres	ICC (25)	RECIST	6 (26) PR	9.3 mo
(2/2010, PC)	(mean 1.76 Gbq)		@ 8.1 mo (median)	11 (48) SD
				5 (22) PD
				2 lost
Haug et al[68]	SIR-Spheres	ICC (26)	RECIST	5 (22) PR	11.7 mo
(6/2011, PC)	(no dosage info)		@ 2.8 mo	15 (65) SD
				3 (13) PD
				3 lost
Hoffmann et al[3]	SIR-Spheres	ICC (33)	RECIST	12 (36) PR	22 mo
(2/2012, RS)	(median 1.54 Gbq)		@ 3 mo	17 (52) SD
				4 (12) PD
Rafi et al[70]	SIR-Spheres	ICC (19)	RECIST	2 (11) PR	11.5 mo
(4/2013, PC)	(mean 1.20 Gbq)		@ 3 mo	13 (68) SD
				4 (21) PD
Mouli et al[74]	Therasphere	ICC (46)	WHO	11 (25) PR	No median OS
(8/2013, PC)	(no dose info)	Note: overlaps with Ibrahim et al	@ 1 mo	33 (73) SD 1 (2) PD	14.6 mo (solitary) 5.7 mo (multifocal)
Camacho et al[72]	SIR-Spheres	ICC (21)	RECIST	RECIST	16.3 mo
(2/2014, PC)	(no dose info)		mRECIST	1 (4.7) PR
			EASL	16 (76.2) SD
			@ 1 mo	4 (19.1) PD
				mRECIST
				13 (62.0) PR
				4 (19.0) SD
				4 (19.0) PD
				EASL
				2 (9.5) PR
				15 (71.4) SD
				4 (19.1) PD
Filippi et al[73]	SIR-Spheres	ICC (18)	PERCIST	14 (82.3) PR	14.8 mo
(8/2014, PC)	(not given)	ICC (18)	@ unspecified	3 (17.6) SD	14.8 mo

ICC: Intrahepatic cholangiocarcinoma; PC: Prospective cohort study; RS: Retrospective study; CR: Complete response; PR: Progressive response; PD: Progressive disease; SD: Stable disease; OS: Overall survival; OR: Overall response.

Table 3 Melanoma studies n (%)

Author	Type of microsphere	Type of mets (patients)	Response criteria	Response	Median OS
(publish date and study type)	(average dosage)	Type of mets (patients)	@ 1^st assessment	Response	Median OS
Xing et al[49]	SIR-Spheres	Melanoma (28)	RECIST 1.1	5/28 (21) PR	10.1 mo
(8/2014, RS)	(mean 1.86 Gbq)	13 cutaneous	@ 0.9-1.4 mo	9/28 (38) SD
		15 ocular		10/28 (42) PD
				4 lost
Memon et al[42]	Therasphere	Melanoma (16)	WHO, RECIST, and EASL	WHO	7.6 mo
(6/2014, RS)	(median 1.87 Gbq)	7 ocular	@ 0.9 mo	5 (31) CR/PR
		3 rectal		8 (50) SD
		4 cutaneous		3 (19) PD
		2 unknown		RECIST
				5 (31) CR/PR
				8 (50) SD
				3 (19) PD
				EASL
				6 (38) CR/PR
				7 (43) SD
				3 (19) PD
Gonsalves et al[37]	SIR-Spheres	Ocular melanoma (32)	RECIST 1.0	1 (3) CR	10.0 mo
(2/2011, RS)	(median 1.08 Gbq)		@ 1 mo	1 (3) PR
				18 (56) SD
				12 (38) PD
Kennedy et al[40]	SIR-Spheres	Ocular melanoma (11)	RECIST	1 (11) CR	Median OS not reached
(7/2009, RS)	(median 1.55 Gbq)		@ 1.4 mo	6 (66) PR
				1 (11) SD
				1 (11) PD
				2 lost
Reiner et al[46]	SIR-Spheres	Melanoma (2, data extracted from larger study)	RECIST 1.1	1 (50) CR/PR	None
(1/2014, PC)	(mean 1.5 Gbq)	Melanoma (2, data extracted from larger study)	@ 4 mo	1 (50) SD/PD	None
Lim et al[41]	SIR-Spheres	Ocular melanoma (1, data extracted from larger study)	RECIST	1 (100) PD	None
(4/2005, PC)	(no dosage info)	Ocular melanoma (1, data extracted from larger study)	@ 2 mo	1 (100) PD	None

PC: Prospective cohort study; RS: Retrospective study; CR: Complete response; PR: Progressive response; PD: Progressive disease; SD: Stable disease; OS: Overall survival; OR: Overall response.

Table 4 Pancreatic cancer studies n (%)

Author	Type of microsphere	Type of mets (patients)	Response criteria	Response	Median OS
(publish date and study type)	(average dosage or activity)	Type of mets (patients)	@ 1^st assessment	Response	Median OS
Michl et al[43]	SIR-Spheres	Pancreatic (19)	RECIST	9/13 (64.3) PR	9 mo
(12/2013, RS)	(1.0-2.5 Gbq)		@ 2.6 mo (median)	4/13 (35.7) PD
				6 lost
Cao et al[32]	SIR-Spheres	Pancreatic (7)	RECIST	2 (40) PR	No median OS
(11/2010, RS)	(no dosage info)		@ 1-2 mo	1 (20) SD	1 patient survived to 15 mo
				2 (40) PD
				2 lost
Pöpperl et al[45]	SIR-Spheres	Pancreatic (1, data extracted from larger study)	PET	1 (100) Regression	None
(4/2005, PC)	(mean 2.27 Gbq)	Pancreatic (1, data extracted from larger study)	@ 3 mo	1 (100) Regression	None

PC: Prospective cohort study; RS: Retrospective study; CR: Complete response; PR: Progressive response; PD: Progressive disease; SD: Stable disease; OS: Overall survival; OR: Overall response.

Table 5 Renal cell carcinoma studies n (%)

Author	Type of microsphere	Type of mets (patients)	Response criteria	Response	Median OS
(publish date and study type)	(average dosage or activity)	Type of mets (patients)	@ 1^st assessment	Response	Median OS
Abdelmaksoud et al[30]	SIR-Spheres	RCC (6)	mRECIST	3 CR (60)	12 mo
(3/2012, RS)	(median 1.89 Gbq)		@ 25 mo (mean)	1 PR (20)
				1 PD (20)
				1 lost
Hamoui et al[38]	Therasphere	RCC (1)	Unspecified	1 (100) SD	Patient died 23 mo after SIRT
(2/2013, case report)	(80 Gy)	RCC (1)	@ 1.8 mo	1 (100) SD	Patient died 23 mo after SIRT

SIRT: Selective internal radiation therapy; RS: Retrospective study; CR: Complete response; PR: Progressive response; PD: Progressive disease; SD: Stable disease; OS: Overall survival.

Table 6 Lung or thoracic cancer studies n (%)

Author	Type of microsphere	Type of mets (patients)	Response criteria	Response	Median OS
(publish date and study type)	(average dosage or activity)	Type of mets (patients)	@ 1^st assessment	Response	Median OS
Gaba et al[36]	Therasphere	Squamous cell lung cancer (2)	PET CT	2 (100) CR	Patient 1: Alive 11 mo after SIRT
(8/2012, case report)	(1.57-3 Gbq)	Squamous cell lung cancer (2)	@ 2-3 mo	2 (100) CR	Patient 2: Alive 2 mo after SIRT
Murthy et al[44]	SIR-Spheres	Lung cancer (6)	Unspecified	1 (17) PR	2.7 mo
(2/2008, RS)	(no dosage info)	2 carcinoids 3 adenocarcinomas	@ unspecified	1 (17) “minor response”
		1 small cell carcinoma		1 (17) SD
				3 (50) PD
Reiner et al[46]	SIR-Spheres	NSCLC (1, data extracted from larger study)	RECIST 1.1	1 (100) CR/PR	None
(1/2014, PC)	(mean 1.5 Gbq)	NSCLC (1, data extracted from larger study)	@ 4 mo	1 (100) CR/PR	None

SIRT: Selective internal radiation therapy; RS: Retrospective study; PC: Prospective cohort study; CR: Complete response; PR: Progressive response; PD: Progressive disease; SD: Stable disease; OS: Overall survival.

Citation: Kuei A, Saab S, Cho SK, Kee ST, Lee EW. Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors. World J Gastroenterol 2015; 21(27): 8271-8283
URL: https://www.wjgnet.com/1007-9327/full/v21/i27/8271.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i27.8271